Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Blood (2024) 144 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2024-199211

Published: 2024

Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Geoff Fisher, Sue Brook, Hendrik-Tobias Arkenau, Ayan Aden Yusuf, Peter Tan

Blood (2024) 144 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2024-210105

Published: 2024

Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Hendrik-Tobias Arkenau, Sue Brook, Charlotte Burmester, Geoff Fisher, Katie Stoddart, Peter Tan

Blood (2023) 142 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2023-188606

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst, Mojca Jongen-Lavrencic, Steffen Boettcher, Geert A. Huls, David C. de Leeuw, Philippe Legenne, Mariola Dymkowska, Christiane Andrieu, Oliver Schönborn-Kellenberger, Paul G. Baverel, Zita Arany, Elena Fernandez, Anne Goubier, Vladimir Kirkin, Nicolas Leupin, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2023-173353

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood (2023) 141 (17): 2114–2126.

https://doi.org/10.1182/blood.2022017333

Published: 2023

Includes: Supplemental data

Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, Jenny O'Nions, Mojca Jongen-Lavrencic, Jeroen J. Janssen, David C. de Leeuw, Peter T. Tan, Sue Brook, Katie Stoddart, Hendrik-Tobias Arkenau, Geoff Fisher

Blood (2022) 140 (Supplement 1): 6222–6223.

https://doi.org/10.1182/blood-2022-166400

Published: 2022

Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei

Blood (2022) 140 (Supplement 1): 7476–7477.

https://doi.org/10.1182/blood-2022-166000

Published: 2022

Journal Articles

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood (2022) 139 (15): 2347–2354.

https://doi.org/10.1182/blood.2021014472

Published: 2022

Includes: Supplemental data

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Geoffrey L Uy, MD, Michael P. Rettig, PhD, Stephanie Christ, MS, Ibrahim Aldoss, MD, Michael T. Byrne, DO, Harry P. Erba, MD PhD, Martha L. Arellano, MD, Matthew C Foster, MD, John E. Godwin, MD, Farhad Ravandi, MBBS, Peter H. Sayre, MDPhD, Anjali S Advani, MD, Matthew J. Wieduwilt, MD PhD, Ashkan Emadi, MD, PhD, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Martin Wermke, Norbert Vey, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Antonio Curti, MDPhD, Geert Huls, MD PhD, Max S. Topp, MD, Mojca Jongen-Lavrencic, MD PhD, John Muth, MS, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MDPhDMS, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-134612

Published: 2020

Journal Articles

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Max S. Topp, MD, Antonio Curti, MDPhD, Farhad Ravandi, MBBS, Michael P. Rettig, PhD, John Muth, MS, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Teia Curtis, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-134576

Published: 2020

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Blood (2019) 134 (Supplement_1): 5144.

https://doi.org/10.1182/blood-2019-127138

Published: 2019

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Farhad Ravandi, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Roland B. Walter, MD PhD MS, Peter Paschka, MD, Mojca Jongen-Lavrencic, MD PhD, Gert J. Ossenkoppele, MD PhD, Zhao Yang, Bhakti Mehta, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 25.

https://doi.org/10.1182/blood-2018-99-109762

Published: 2018

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

Journal Articles

Identification of Novel Lncrnas That Predict Survival in AML Patients and Modulate Leukemic Cells

Sarah Grasedieck, MSc, Christoph Rueß, MSc, Nicole Pochert, MSc, Susanne Lux, MSc, Adrian Schwarzer, MD PhD, Jan-Henning Klusmann, Mojca Jongen-Lavrencic, MD PhD, Jonathan R. Pollack, MD PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD PhD

Blood (2018) 132 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2018-99-118331

Published: 2018

NARROW

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Identification of Novel Lncrnas That Predict Survival in AML Patients and Modulate Leukemic Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only